What’s New in the AACE/ACE Diabetes 2016 Algorithm?

Pharmacotherapy for Cardiovascular Comorbidities

Patients with dyslipidemia can be treated with a variety of agents, depending on their particular abnormality. Agents include statin drugs, fibrates, prescription-strength omega-3 fatty acids, niacin, ezetimibe, proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors, and colesevelam. For patients with hypertension, recommended agents include angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor II blockers (ARBs), calcium channel blockers, beta-blockers, and thiazides. Patients should be reassessed at two- to three-month intervals, adding agents as necessary. Additional choices include alpha-blockers, central agents, vasodilators, and aldosterone antagonists.


The authors state that their algorithm “was developed to provide clinicians with a practical guide that considers the whole patient, their spectrum or risks and complications, and evidence-based approaches to treatment.”1 The algorithm includes the most updated information and guidance available to assist clinicians in making the myriad complex decisions in managing the increasing number of patients affected by T2D.


1.      Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of clinical Endocrinologists and American College of Endocrinology on the comprehensive Type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract. 2016;22(1):84-113.

2.      Garber AJ, Abrahamson MJ, Barzilay JI, et al. American Association of Clinical Endocrinologists’ comprehensive diabetes management algorithm 2013 consensus statement–executive summary. Endocr Pract. 2013;19(3):536-57.